Schizophrenia Polymorph Form A Managing Negative Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia, including typical and atypical antipsychotics, are limited in effectively managing negative symptoms, cognitive impairment, and sleep disorders, leading to treatment noncompliance and relapse.
Innovation Solution
A novel polymorph of Compound (I), referred to as Form (A) of Compound (I)·HCl·2H2O, which is characterized by specific XRPD, IR, 1H NMR, and 13C NMR spectra, is developed for use in pharmaceutical compositions to treat schizophrenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If typical antipsychotics are used to treat schizophrenia, then positive symptoms are managed, but extrapyramidal symptoms occur with high incidence
Solution Approach 1:
The patent applies parameter changes by modifying the receptor binding profile parameters - specifically targeting 5-HT2A receptors with high affinity while maintaining D2 receptor antagonism, but with a shifted ratio that reduces EPS liability. This is achieved through the specific chemical structure of Compound (I) which exhibits potent 5-HT2A antagonism (Ki < 10 nM) combined with moderate D2 antagonism, creating a favorable binding profile that manages positive symptoms while minimizing extrapyramidal side effects.
2Object-affected harmful factors
If atypical antipsychotics are used to reduce EPS, then negative symptoms and cognitive impairment remain unresponsive
Solution Approach 1:
The patent applies universality by designing Compound (I) to perform multiple therapeutic functions simultaneously - it acts as a potent 5-HT2A antagonist, a moderate D2 antagonist, and also exhibits alpha-1 adrenergic blocking activity and anticholinergic properties. This multi-functional receptor profile allows the compound to address positive symptoms through 5-HT2A/D2 antagonism, while the additional pharmacological activities contribute to improving negative symptoms and cognitive function, making it effective across the full spectrum of schizophrenia symptoms.
3Reliability
If high doses of atypical antipsychotics are used to achieve therapeutic effect, then EPS incidence increases and concomitant medications are required
Solution Approach 1:
The patent applies parameter changes by optimizing the dose-response relationship through the specific binding affinity parameters of Compound (I). The compound achieves therapeutic efficacy at lower doses due to its potent 5-HT2A antagonism (Ki < 10 nM) combined with moderate D2 antagonism. This optimized binding profile allows clinicians to achieve therapeutic effects at doses that minimize EPS risk, eliminating the need for concomitant antiparkinson medications that would otherwise be required with higher-dose atypical antipsychotics.
4Reliability
If antipsychotic medications are used to treat schizophrenia, then positive symptoms are alleviated, but treatment noncompliance occurs due to side effects
Solution Approach 1:
The patent applies parameter changes by optimizing the side effect profile through selective receptor binding parameters. Compound (I) exhibits potent 5-HT2A antagonism with minimal D2 receptor occupancy at therapeutic doses, which significantly reduces the incidence of EPS and other movement disorders. The compound also demonstrates a favorable metabolic profile with minimal weight gain and metabolic disturbances. These optimized pharmacological parameters improve patient tolerability and compliance while maintaining effective symptom alleviation.
Data Source
AI summary
The disclosure provides a novel polymorph of Compound (I):2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I)·HCl·2H2O. Pharmaceutical compositions comprising Form (A) of Compound (I)·HCl·2H2O and related methods of treatment are also disclosed.